The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
Open accessAbstract
BACKGROUND: The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS: We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). RESULTS: The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. CONCLUSIONS: Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite 5–10% weight loss in trials, it was discontinued in 2010 after the SCOUT trial showed elevated cardiovascular events (e.g., stroke) in high-risk patients [4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the concept of treating obesity to reduce the risk of cardiovascular complications has been hampered by the lack of evidence from trials indicating that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes. 11-15”
From Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023) · cites this paper as [13]
In the citing paper
“Prospective studies that evaluated the effect of nonsurgical weight loss interventions on CV event reduction have been disappointing [4, 5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [5]
In the citing paper
“Specifically, across the obesity CVOTs, SELECT is the only study to our knowledge that only enrolled participants with established CVD, whereas in the other obesity CVOTs, 24.9% to 50.5% of participants had no prior events [5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572
S UCCESSFUL W EIGHT L OSS M AINTENANCE
Wing, R. R., & Hill, J. O. (2001) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.21.1.323 · Cited by 1,382
Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis
Dattilo, A., & Kris-Etherton, P. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/56.2.320 · Cited by 1,055
Secular Trends in Cardiovascular Disease Risk Factors According to Body Mass Index in US Adults
Gregg, E. W. (2005) · JAMA · doi:10.1001/jama.293.15.1868 · Cited by 959
Blood Pressure Lowering Treatment Trialists’ Collaboration (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1410 · Cited by 789
Flagged first, then by citations
Research works printed but not linked: 3
- 1996, Can J Cardiol, 12, 127
- 1994, Lancet, 344, 1383
- Lyznicki JM, 2001, Am Fam Physician, 63, 2185
Cited by
Sorted by citations
Items 801–900 of 943
NET‐NET: Are Norepinephrine Transport Inhibitors a Potentially Useful Therapy for Vasovagal Syncope?
Roukoz, H., & Benditt, D. G. (2013) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12136
The Cardiovascular Spectrum of Adverse Drug Reactions
Schubert, C., & Hsia, J. A. (2014) · doi:10.1002/9781118820186.ch38
Armando Pérez, M., Aure, G., & Ruíz-Contreras, J. (2012) · Revista Venezolana de Endocrinología y Metabolismo
Alzahrani, A. H. (2014) · The Sydney eScholarship Repository (The University of Sydney)
New and emerging drugs for the treatment of obesity
Roh, E., & Kim, M. (2015) · Journal of Korean Medical Association · doi:10.5124/jkma.2015.58.5.452
Obesity: The Elephant in the Room
Cooper, K., Schauer, P. R., Brethauer, S. A., & Kashyap, S. R. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1198-7_20
Adeyemi, A. (2014) · Texas ScholarWorks (Texas Digital Library)
Bolusani, H. (2013) · ORCA Online Research @Cardiff (Cardiff University)
Médicaments de l’obésité et risque cardiovasculaire
Scheen, A. J., & Gaal, L. F. V. (2012) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(12)70352-8
Long-term health benefits of appetite suppressants remain unproven
Paumgartten, F. J. R. (2011) · Revista de Saúde Pública · doi:10.1590/s0034-89102011005000075
Unfeasibility of a risk mitigation strategy for sibutramine
Paumgartten, F. J. R. (2012) · Brazilian Journal of Psychiatry · doi:10.1016/s1516-4446(12)70021-1
The dismal fat, kidney and brain connection: what to do?
Reuter, J., & Jordan, J. (2011) · Hypertension Research · doi:10.1038/hr.2011.85
Vlasova, I. I., & As, A. (2012) · Problems of Endocrinology · doi:10.14341/probl201258134-38
Best Clinical Trials Reported in 2010
Garner, J. B., Grayburn, P. A., & Yancy, C. W. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.02.354
Buehler (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s77881
SADIKOT, S. M. (2010) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2010.11.001
An Approach to Obesity as a Cardiometabolic Disease: Potential Implications for Clinical Practice
(2014) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608059140114020003
It Is Important Research, but Why Is It Necessary?
Woosley, R. L. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.15
Recent Publications on Medications and Pharmacy
Russett, F. (2012) · Hospital Pharmacy · doi:10.1310/hpj4705-401
Therapies for Obesity Management
Tran-Kerr, K. (2015)
Sjöström, L., Peltonen, M., Jacobson, P., Ahlin, S., Andersson‐Assarsson, J. C., Anveden, Å., Bouchard, C., Carlsson, B., Karason, K., Lönroth, H., et al. (2015)
Maggioni, L. (2014) · Americanae (AECID Library)
Use of Multiple Biomarkers to Estimate Cardiovascular Drug Efficacy: Advantage of a PRE Score
Smink, P. A., & Heerspink, H. J. L. (2016) · Springer eBooks · doi:10.1007/978-94-007-7678-4_47
Obesidade - Revisão Bibliográfica
da Saúde, C. (2011)
Franco, R. R., Cominato, L., & Damiani, D. (2014)
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
Elliott, W. J. (2011) · Yearbook of Cardiology · doi:10.1016/j.ycar.2011.01.121
Kozak, B. M., Deming, H. C., Tjota, M. Y., & Close, K. L. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2012.00219.x
Chang, E., Kozak, B., & Close, K. L. (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00097.x · Cited by 1
Mietlicki‐Baase, E. G., & Hayes, M. R. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_25-1
Tendencies in medical publications
Tamez-Pérez, H. E., Delgadillo-Esteban, E., Peña, S. L. P., Arenas‐Fabbri, V., Carranza-Trejo, A. M., González‐González, J. G., & Tamez-Peña, A. L. (2015) · Medicina Universitaria · doi:10.1016/j.rmu.2015.04.002
Surgical treatment of severe obesity with laparoscopic gastric bypass and duodenal switch
Søvik, T. T. (2012) · NORA - Norwegian Open Research Archives
Bioactives in Overweight and Obesity
Kumar, V. (2016) · International Journal of Medical and Dental Sciences · doi:10.19056/ijmdsjssmes/2016/v5i2/100590
Off-target effects of RAAS-inhibition
Yan, M. (2012)
Biomarkers and assessment of drug efficacy in cardiovascular disease
Smink, P. A. (2013) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Individual interventions to treat obesity
Townsend, N. P., & Scriven, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-7020-4634-6.00005-4
Experimental Studies of Subdiaphragmatic Vagotomy and Nicotine for Reducing Body Weight
Dezfuli, G. (2014) · DigitalGeorgetown (Georgetown University Library)
The preproglucagon derived peptides and energy homeostasis
Parker, J. (2013) · doi:10.25560/10956
Past, Present, and Future of Drug Safety Assessment
Temple, R. (2012) · Lecture notes in statistics · doi:10.1007/978-1-4614-5245-4_10
Sibutramine Raises Risk for Adverse Cardiovascular Events
Brett, A. S. (2010) · Journal watch · doi:10.1056/jw201009020000002
Maćkowska-Kędziora, A. (2015)
Revista Brasileira de Psiquiatria
Paumgartten, F. J. R., de Saúde, E. N., & Cl, R. (2012)
Forrest, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-53097-0_5
Immobilization of Lipase Inhibitor on the Biopolymers of Agaricus bisporus Cell Walls
Cherno, N., Osolina, S., & Нікітіна, О. В. (2017) · Food Technology and Biotechnology · doi:10.17113/ftb.55.04.17.4911
Phase IV Trials: Interventional and Non-interventional Studies
Uema, D., Yen, C. T., Hinke, A., & de Castro, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-71324-3_13
Naffouje, S. A., & Salti, G. I. (2018) · Springer eBooks · doi:10.1007/978-3-319-93545-4_40
Sultan, A. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70772-2
Demerdash, H. M., Hady, S. A., & Kandil, L. S. (2018) · Obesity Research - Open Journal · doi:10.17140/oroj-5-135
Heart Failure and Metabolic Factors
Nilsson, P. M., Molvin, J., & Magnusson, M. (2019) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-93320-7_8
Prevention of cardiovascular diseases in the obese
Svacina, S. (2011) · Cor et Vasa · doi:10.33678/cor.2011.053
Galtier, F., & Bringer, J. (2015) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30885-4
Use of diuretics in hypertensive patients with metabolic disturbances
Валерьевна, Ж. Ю., & Chazova, I. E. (2013) · Systemic Hypertension · doi:10.26442/sg28964
Anti-Obesity Medications: An Update for Canadian Physicians
Modi, R., Kabani, R., Dang, J. T., Chapelsky, S., & Sharma, A. M. (2020) · Canadian Journal of General Internal Medicine · doi:10.22374/cjgim.v15i4.394
Self-citationInfarto agudo del miocardio asociado a uso de anorexígenos: Realidad o mito?
Muñoz-Gutiérrez, E., & Alvarez-Cabrera, M. C. (2011) · Lux Médica · doi:10.33064/17lm20111659
BINGE EATING DISORDERS; UPDATED AND EMERGING APPROACHES
Teaima, M. H. M., Hamid, M. M. A., Shoman, N. A., Jasti, B., El-Nabarawi, M. A., & Yasser, M. (2021) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2021v13i2.40214 · Cited by 1
Obesity and schizophrenia: New drugs, new hopes
Miljević, Č., & Vuković, O. (2020) · Psihijatrija danas · doi:10.5937/psihdan2001113m
State-of-the-Art Drug Therapies of Obesity
Antsiferov, M. B., Moscow, R. F., & Markova, T. N. (2021) · Doctor Ru · doi:10.31550/1727-2378-2021-20-2-45-50
Peptide/Receptor Evolution Explains the Lipolytic Function of the Neuropeptide TLQP-21Preprint
Sahu, B. S., Han, R., Cero, C., Razzoli, M., Rodriguez, P. J., Nguyen, M. E., Piaggi, P., Pavličev, M., Muglia, L. J., Mahata, S. K., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3341735
Olğar, Y., Alyu, F., Öztürk, Y., & Turan, B. (2021) · Journal of Ankara University Faculty of Medicine · doi:10.4274/atfm.galenos.2020.17363
김미경 (2013)
Antidiabetika: Gewichtsreduktion als wünschenswerter Begleiteffekt
Wirth, A. G. (2011) · Der Internist
Development and Evaluation of a Beverage that Forms Bubble-Containing Gel in the Stomach
Domoto, T., & ドウモト, タ. (2020) · Terrestrial Environment Research Center (University of Tsukuba)
A Review on Effects of Cardiotoxic Drugs in Animal Models
Alsuwayt, B. (2021) · Journal of Liaquat University of Medical & Health Sciences · doi:10.22442/jlumhs.2021.00827
Guidoni, C. M., & Pereira, L. R. L. (2012) · DOAJ (DOAJ: Directory of Open Access Journals)
Heisler, L. K., & D’Agostino, G. (2014) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718163291.793490349
Basu, A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736550002.793571773
Advances in Pharmacological Treatment of Pediatric Obesity
Goran, M. I. (2016) · CRC Press eBooks · doi:10.1201/9781315370958-31
Mietlicki‐Baase, E. G., & Hayes, M. R. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_25
(2014) · Elsevier eBooks · doi:10.1016/b978-0-7020-4634-6.09985-4
Proceedings of the Congress Antidotes in Depth 2011. Pavia, 28-30 Sept. 2011
Editors, T. (2011) · Emergency Care Journal · doi:10.4081/ecj.2011.4.29
Weight loss methods and diet history among bariatric surgery candidates
Guilbert, L., Sahagún, C. M. V., Guerrero, E., Licona, C. G. C., Escobedo, S. U. P., & Zerrweck, C. (2022) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20221173
Use of Multiple Biomarkers to Estimate Cardiovascular Drug Efficacy: Advantage of a PRE Score
Smink, P. A., & Heerspink, H. J. L. (2015) · Springer eBooks · doi:10.1007/978-94-007-7741-5_47-1
USE OF PHARMACOTHERAPY FOR WEIGHT LOSS
(2011) · Nutrition & Dietetics · doi:10.1111/j.1747-0080.2011.01523.x
Smith, S. R. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1028-7_15
&NA; (2011) · Drugs & Therapy Perspectives · doi:10.2165/11601710-000000000-00000
Kozak, B. M., Tjota, M. Y., & Close, K. L. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00104.x
Morgan, C., de Wildt, G., Virmond, M., Riley, R. A., Thanikachalam, N., & Prado, R. B. R. (2020) · doi:10.21203/rs.2.21048/v1
Salim, S. A., Keri, K., & Agarwal, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-57460-4_21
Risque cardiovasculaire et sibutramine
(2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70135-8
Goudarzi, F., Najafi, N., Azarpira, N., Tavakoli, N., & Najafi, Z. (2016) · Jundishapur Journal of Natural Pharmaceutical Products · doi:10.17795/jjnpp-34602
Sibutramine, Phentermine, and Diethylpropion: Sympathomimetic Drugs in the Management of Obesity
Bray, G., & Bouchard, C. (2014) · CRC Press eBooks · doi:10.1201/b16472-23
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01447-5
(2012) · Elsevier eBooks · doi:10.1016/b978-0-323-08373-7.00024-8
Obesity Hypertension: Clinical Aspects
Macumber, I. R., & Flynn, J. T. (2022) · Springer eBooks · doi:10.1007/978-3-319-31420-4_17-2
A súlyfelesleg és annak csökkentése kardiovaszkuláris szempontból
Bajnok, L. (2021) · Cardiologia Hungarica · doi:10.26430/chungarica.2021.51.5.331 · Cited by 1
The pharmacological treatment of obesity: A historical perspective
Cuenca-Ecuador., U. C. D. C., Pacheco, A. V. G., Peláez, C. E. A., & Ortíz, R. (2022) · Gaceta Médica de Caracas · doi:10.47307/gmc.2022.130.s3.27
The Role of Primary Care in Bariatric Surgery
Haslam, D. W., Hinchliffe, N., & Capehorn, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-54064-7_74-1
SIBUTRAMINE: THE MAGIC PILL TO LOSE WEIGHT AND INCREASE CARDIOVASCULAR RISKS
Amorim, V. E. M., Santos, A. C. B. C., Filho, D. S., da Silva, F. S., Aureliano, P. C. A., Saraiva, M. B. B., de Martino, V., dos Santos, I. L., Brito, T. M., da Silva, G. J., et al. (2023) · International Journal of Health Science · doi:10.22533/at.ed.1593262310048
МЕДИКО-СОЦИАЛЬНЫЕ АСПЕКТЫ ПРОБЛЕМЫ ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ МОРБИДНОГО ОЖИРЕНИЯ (Обзор литературы)
Ботиров, А., & Расулов, М. (2023) · Medical science of Uzbekistan · doi:10.56121/2181-3612-2023-2-04-08
Pharmacology of Anti-Obesity Medications: Current Status and Future Needs
Clements, J. N. (2023) · Medical Research Archives · doi:10.18103/mra.v11i6.3849
Anti-Obesity Effects of Menthae Herba Hydrosol on High-Fat Diet Induced Obese Mice
Choi, S.-M., Kim, S. Y., Kim, Y., Woo, C., Kim, M.-R., & An, H.-D. (2023) · Journal of Korean Medicine Rehabilitation · doi:10.18325/jkmr.2023.33.3.33
Mendes, R. R., & Prado, J. R. S. (2023) · Revista Brasileira de Fisiologia do Exercício · doi:10.33233/rbfex.v22i1.5468
Сучасні підходи до комплексного лікування ожиріння з пацієнторієнтованим підходом
Tkachenko, V. I., & Bagro, T. (2023) · Health of Society · doi:10.22141/2306-2436.12.2.2023.305
Finer, N. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch18
Self-citation
Metadata
- Authors
- James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., & Renz, C. L.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- The University of Sydney (AU)
- Pontifícia Universidade Católica do Rio de Janeiro (BR)
- University College London (GB)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- Gentofte Hospital (DK)
- University of Alberta (CA)
- Abbott (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-02
- Volume
- 363
- Issue
- 10
- Pages
- 905-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2119779723
- Cited by
- 943
- References
- 33
- Citations by year
- 2026: 27 · 2025: 43 · 2024: 50 · 2023: 40 · 2022: 35 · 2021: 50 · 2020: 45 · 2019: 36 · 2018: 54 · 2017: 38 · 2016: 63 · 2015: 69 · 2014: 75 · 2013: 91 · 2012: 93
- FWCI
- 75.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- UCrea (University of Cantabria) (submittedVersion, cc-by)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- ORBi (University of Liège) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- University of Cambridge
- Eisai
- Novo Nordisk
- Shionogi
- Servier
- Allergan
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- sibutramine, cardiovascular outcomes, obesity, overweight, weight management, cardiovascular risk, myocardial infarction, stroke, cardiovascular mortality, type 2 diabetes, blood pressure, weight loss, older adults, drug safety, appetite suppressants, anti-obesity drugs, cardiovascular events, cardiovascular risk reduction, cardiovascular risk stratification
- MeSH terms
- Aged, Appetite Depressants, Blood Pressure, Cardiovascular Diseases, Cyclobutanes, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Obesity, Stroke, Overweight, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
